A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice
Launched by NOVO NORDISK A/S · Aug 1, 2019
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed consent obtained before any study-related activities. Study-related activities are any procedures related to recording of data according to the protocol.
- • The decision to initiate or switch into treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before, and independently from, the decision to include the patient in this study.
- • Male or female, age above or equal to 18 years at the time of signing informed consent.
- • Diagnosed with T2DM and treated with any anti-hyperglycaemic medication(s) other than Ryzodeg® for at least 26 weeks prior to signing informed consent.
- • Available and documented HbA1c value for 12 weeks or less prior to signing informed consent.
- Exclusion Criteria:
- • Hypersensitivity to the active substance or to any of the excipients as specified in the Ryzodeg® local label.
- • Previous participation in this study. Participation is defined as signed informed consent.
- • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
- • Previous treatment with Ryzodeg®.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Herston, Queensland, Australia
St Leonards, New South Wales, Australia
Elizabeth Vale, South Australia, Australia
St Leonards, New South Wales, Australia
Hobart, Tasmania, Australia
Melbourne, Victoria, Australia
Kota Bharu, Kelantan, , Malaysia
Davao City, , Philippines
Pretoria, Gauteng, South Africa
Wollongong, New South Wales, Australia
Quezon City, , Philippines
Quezon City, , Philippines
Elizabeth Vale, South Australia, Australia
Port Elizabeth, Eastern Cape, South Africa
Manila, , Philippines
Melbourne, Victoria, Australia
Keswick, South Australia, Australia
Box Hill, Victoria, Australia
Johannesburg, Gauteng, South Africa
Davao City, , Philippines
Makati City, , Philippines
Bloemfontein, , South Africa
Putrajaya, , Malaysia
Alberton, , South Africa
Herston, Queensland, Australia
Lenasia, Gauteng, South Africa
South Brisbane, Queensland, Australia
Chennai, Tamil Nadu, India
Port Elizabeth, Eastern Cape, South Africa
Penang, , Malaysia
Penang, , Malaysia
Mohali, Punjab, India
Port Elizabeth, Eastern Cape, South Africa
New Delhi, , India
South Brisbane, Queensland, Australia
Nagpur, Maharashtra, India
New Delhi, , India
Putrajaya, , Malaysia
Jeddah, , Saudi Arabia
Bhubaneswar, Orissa, India
Jeddah, , Saudi Arabia
Riyadh, , Saudi Arabia
Guwahati, Assam, India
Berea, Kwazulu Natal, South Africa
Bhubaneswar, Orissa, India
Cooloongup, Western Australia, Australia
Bangalore, Karnataka, India
Delhi, New Delhi, India
Howrah, West Bengal, India
Kedah, , Malaysia
Kelantan, , Malaysia
Kuala Lumpur, , Malaysia
Kuching, , Malaysia
Melaka, , Malaysia
Perak, , Malaysia
Perlis, , Malaysia
Selangor, , Malaysia
Aklan, , Philippines
Cebu City, , Philippines
Iloilo, , Philippines
Makati City, , Philippines
Manila, , Philippines
Makkah, , Saudi Arabia
Cooloongup, Western Australia, Australia
Manila, , Philippines
Guwahati, Assam, India
Mohali, Punjab, India
Johannesburg, Gauteng, South Africa
Pretoria, Gauteng, South Africa
Wollongong, New South Wales, Australia
Jeddah, , Saudi Arabia
Lenasia, Gauteng, South Africa
Jeddah, , Saudi Arabia
Berea, Kwazulu Natal, South Africa
Keswick, South Australia, Australia
Hobart, Tasmania, Australia
Box Hill, Victoria, Australia
Bangalore, Karnataka, India
Bangalore, Karnataka, India
Nagpur, Maharashtra, India
Delhi, New Delhi, India
Chennai, Tamil Nadu, India
Howrah, West Bengal, India
Kedah, , Malaysia
Kelantan, , Malaysia
Kota Bharu, Kelantan, , Malaysia
Kuala Lumpur, , Malaysia
Kuching, , Malaysia
Kuching, , Malaysia
Melaka, , Malaysia
Melaka, , Malaysia
Perak, , Malaysia
Perlis, , Malaysia
Selangor, , Malaysia
Selangor, , Malaysia
Aklan, , Philippines
Cebu City, , Philippines
Iloilo, , Philippines
Manila, , Philippines
Quezon City, , Philippines
Quezon City, , Philippines
Jeddah, , Saudi Arabia
Jeddah, , Saudi Arabia
Makkah, , Saudi Arabia
Riyadh, , Saudi Arabia
Riyadh, , Saudi Arabia
Riyadh, , Saudi Arabia
Riyadh, , Saudi Arabia
Port Elizabeth, Eastern Cape, South Africa
Alberton, , South Africa
Bloemfontein, , South Africa
Patients applied
Trial Officials
Clinical Reporting Anchor and Disclosure (1452)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials